

Agenda

Technology Networks

Technology Spotlight: Target-Based Drug Discovery

February 26, 2026 8am PST | 11am EST | 4pm GMT | 5pm CET

Join us for an engaging webinar exploring how advances in target-based drug discovery are transforming the way therapeutics are designed and developed. This webinar will examine innovations in structure-based design, computational modeling and validation strategies that are streamlining the identification and optimization of novel drug targets.

Attend this webinar to:

- Understand current barriers that limit efficiency and success in traditional drug discovery pipelines
- Identify strategies to evaluate existing drugs for potential activity in new disease contexts
- Understand how Design–Make–Test–Decide principles apply to large-molecule and molecular biology discovery workflows

TALK 1

Old Drugs, New Tricks: The Benefits of Re-Purposing

Presented by Dr. Ben Greulich, Mercer University School of Medicine

A critical challenge in drug development is the inefficiency of the traditional discovery pipeline, where only 1 in roughly 10,000 candidates reaches the market due to issues like low efficacy or high toxicity. Re-purposing existing drugs offers an alternative strategy, leveraging compounds already validated for safety and efficacy to explore novel therapeutic applications.

In this session, Dr. Ben Greulich from Mercer University School of Medicine will discuss the potential of drug re-purposing, emphasizing how biological systems naturally re-use proteins and pathways across multiple conditions. He will highlight the advantages of redirecting validated drugs toward new disease contexts to accelerate therapeutic development.

In his talk, he will:

- Explain why traditional drug discovery is inefficient and how re-purposing can improve success rates
- Illustrate how existing drugs can be applied to new diseases by leveraging shared molecular targets
- Discuss the benefits and opportunities of drug re-purposing alongside ongoing efforts to develop novel compounds

TALK 2

Design–Make–Test–Decide for Large-Molecule Drug Discovery

Presented by Zev Wisotsky, Director of Drug Discovery Biologics at Revvity Signals

A key challenge in large-molecule drug discovery is coordinating design, experimentation and decision-making across fragmented workflows built from disconnected tools, spreadsheets and manual processes. These inefficiencies slow iteration, reduce traceability and hinder team collaboration.

In this session, Zev Wisotsky, Director of Drug Discovery Biologics at Revvity Signals, will introduce the Design–Make–Test–Decide (DMTD) framework, which integrates molecular design with experimental execution and analytics to enable continuous iteration and informed decisions.

In his talk, he will:

- Explain how fragmented workflows impede large-molecule drug discovery and the benefits of a unified approach
- Show how DMTD integrates molecular biology design with downstream data to support faster, more confident decision-making
- Discuss how cohesive DMTD workflows improve collaboration, reduce friction and accelerate the discovery lifecycle